AKR1C1 and cholangiocarcinoma: According to recent reports, avasimibe can inhibit the progression of cholangiocarcinoma by targeting the FoxM1-AKR1C1 signalling pathway and induce apoptosis and cycle arrest to inhibit glioma tumour growth [32, 33].